Literature DB >> 29669796

PRDM4 mediates YAP-induced cell invasion by activating leukocyte-specific integrin β2 expression.

Huan Liu1, Xiaoming Dai1, Xiaolei Cao1, Huan Yan1, Xinyan Ji1, Haitao Zhang1, Shuying Shen1, Yuan Si1, Hailong Zhang2, Jianfeng Chen2, Li Li3, Jonathan C Zhao4, Jindan Yu4, Xin-Hua Feng1, Bin Zhao5.   

Abstract

Yes-associated protein (YAP) is a transcriptional co-activator and a major effector of the Hippo pathway that promotes cell proliferation and stemness, while inhibiting apoptosis. YAP plays a central role in organ size control, and its deregulation strongly promotes cancer initiation and progression. However, the mechanisms by which YAP promotes cell invasion and metastasis are not fully understood. Here, we report that YAP induces leukocyte-specific integrin β2 (ITGB2) expression in cancer cells, thereby promoting cell invasion through the endothelium in a manner mimicking leukocytes. Through independent biochemical purification and a functional screen, we further identified PR/SET domain 4 (PRDM4) as a transcription factor interacting with the WW domains of YAP to mediate ITGB2 expression and cell invasion. Consistently, ITGB2 and PRDM4 mRNA levels are significantly increased in metastatic prostate cancer. In addition, PRDM4 contributes to YAP-induced tumorigenesis possibly via mediating the expression of other YAP target genes. Our results demonstrate that YAP promotes cell invasion by inducing leukocyte-specific integrin expression, and identify PRDM4 as a novel transcription factor for YAP targets.
© 2018 The Authors.

Entities:  

Keywords:  Hippo pathway; ITGB2; PRDM4; cell invasion; yes‐associated protein

Mesh:

Substances:

Year:  2018        PMID: 29669796      PMCID: PMC5989780          DOI: 10.15252/embr.201745180

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  67 in total

Review 1.  The regulation of integrin function by divalent cations.

Authors:  Kun Zhang; JianFeng Chen
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

2.  TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway.

Authors:  Qun-Ying Lei; Heng Zhang; Bin Zhao; Zheng-Yu Zha; Feng Bai; Xin-Hai Pei; Shimin Zhao; Yue Xiong; Kun-Liang Guan
Journal:  Mol Cell Biol       Date:  2008-01-28       Impact factor: 4.272

Review 3.  Crossing the endothelial barrier during metastasis.

Authors:  Nicolas Reymond; Bárbara Borda d'Água; Anne J Ridley
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

4.  YAP Regulates Actin Dynamics through ARHGAP29 and Promotes Metastasis.

Authors:  Yiting Qiao; Jianxiang Chen; Ying Bena Lim; Megan Louise Finch-Edmondson; Veerabrahma Pratap Seshachalam; Lei Qin; Tingting Jiang; Boon Chuan Low; Himanshu Singh; Chwee Teck Lim; Marius Sudol
Journal:  Cell Rep       Date:  2017-05-23       Impact factor: 9.423

5.  Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65.

Authors:  Elizabeth M Morin-Kensicki; Brian N Boone; Michael Howell; Jaclyn R Stonebraker; Jeremy Teed; James G Alb; Terry R Magnuson; Wanda O'Neal; Sharon L Milgram
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

6.  YAP1 increases organ size and expands undifferentiated progenitor cells.

Authors:  Fernando D Camargo; Sumita Gokhale; Jonathan B Johnnidis; Dongdong Fu; George W Bell; Rudolf Jaenisch; Thijn R Brummelkamp
Journal:  Curr Biol       Date:  2007-11-01       Impact factor: 10.834

7.  Toward a Shared Vision for Cancer Genomic Data.

Authors:  Robert L Grossman; Allison P Heath; Vincent Ferretti; Harold E Varmus; Douglas R Lowy; Warren A Kibbe; Louis M Staudt
Journal:  N Engl J Med       Date:  2016-09-22       Impact factor: 91.245

8.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

9.  Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

Authors:  Xiaodong Feng; Maria Sol Degese; Ramiro Iglesias-Bartolome; Jose P Vaque; Alfredo A Molinolo; Murilo Rodrigues; M Raza Zaidi; Bruce R Ksander; Glenn Merlino; Akrit Sodhi; Qianming Chen; J Silvio Gutkind
Journal:  Cancer Cell       Date:  2014-05-29       Impact factor: 31.743

10.  The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals.

Authors:  Nailing Zhang; Haibo Bai; Karen K David; Jixin Dong; Yonggang Zheng; Jing Cai; Marco Giovannini; Pentao Liu; Robert A Anders; Duojia Pan
Journal:  Dev Cell       Date:  2010-07-20       Impact factor: 12.270

View more
  14 in total

Review 1.  An overview of signaling pathways regulating YAP/TAZ activity.

Authors:  Boon Chin Heng; Xuehui Zhang; Dominique Aubel; Yunyang Bai; Xiaochan Li; Yan Wei; Martin Fussenegger; Xuliang Deng
Journal:  Cell Mol Life Sci       Date:  2020-08-03       Impact factor: 9.261

2.  YAP1 acts as a negative regulator of pro-tumor TAZ expression in esophageal squamous cell carcinoma.

Authors:  Yi-Zih Kuo; Ya-Rong Kang; Wei-Lun Chang; Lydia Chin-Ling Sim; Tzu-Chin Hsieh; Chu-Han Chang; Yi-Ching Wang; Ching-Jung Tsai; Li-Chun Huang; Sen-Tien Tsai; Li-Wha Wu
Journal:  Cell Oncol (Dordr)       Date:  2022-08-05       Impact factor: 7.051

3.  Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor.

Authors:  Rebecca E Vargas; Vy Thuy Duong; Han Han; Albert Paul Ta; Yuxuan Chen; Shiji Zhao; Bing Yang; Gayoung Seo; Kimberly Chuc; Sunwoo Oh; Amal El Ali; Olga V Razorenova; Junjie Chen; Ray Luo; Xu Li; Wenqi Wang
Journal:  EMBO J       Date:  2019-11-29       Impact factor: 11.598

4.  PRDM4 inhibits cell proliferation and tumorigenesis by inactivating the PI3K/AKT signaling pathway through targeting of PTEN in cervical carcinoma.

Authors:  Wen-Ting Yang; Mei Chen; Rui Xu; Peng-Sheng Zheng
Journal:  Oncogene       Date:  2021-04-12       Impact factor: 9.867

5.  Intracellular Fate and Impact on Gene Expression of Doxorubicin/Cyclodextrin-Graphene Nanomaterials at Sub-Toxic Concentration.

Authors:  Daniela Caccamo; Monica Currò; Riccardo Ientile; Elisabetta Am Verderio; Angela Scala; Antonino Mazzaglia; Rosamaria Pennisi; Maria Musarra-Pizzo; Roberto Zagami; Giulia Neri; Consolato Rosmini; Monica Potara; Monica Focsan; Simion Astilean; Anna Piperno; Maria Teresa Sciortino
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

6.  miR-129-5p inhibits prostate cancer proliferation via targeting ETV1.

Authors:  Ge Gao; Dianhui Xiu; Bin Yang; Daju Sun; Xin Wei; Youpeng Ding; Yanan Ma; Zhixin Wang
Journal:  Onco Targets Ther       Date:  2019-05-09       Impact factor: 4.147

7.  Special Issue on "Disease and the Hippo Pathway".

Authors:  Carsten Gram Hansen
Journal:  Cells       Date:  2019-09-30       Impact factor: 6.600

Review 8.  Multifaceted Role of PRDM Proteins in Human Cancer.

Authors:  Amelia Casamassimi; Monica Rienzo; Erika Di Zazzo; Anna Sorrentino; Donatella Fiore; Maria Chiara Proto; Bruno Moncharmont; Patrizia Gazzerro; Maurizio Bifulco; Ciro Abbondanza
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923

9.  Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival.

Authors:  Hugo Murua Escobar; Ingo Nolte; José Luis Granados-Soler; Kirsten Bornemann-Kolatzki; Julia Beck; Bertram Brenig; Ekkehard Schütz; Daniela Betz; Johannes Junginger; Marion Hewicker-Trautwein
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

10.  ITGB2-mediated metabolic switch in CAFs promotes OSCC proliferation by oxidation of NADH in mitochondrial oxidative phosphorylation system.

Authors:  Xiaoxin Zhang; Yingchun Dong; Mengxiang Zhao; Liang Ding; Xihu Yang; Yue Jing; Yuxian Song; Sheng Chen; Qingang Hu; Yanhong Ni
Journal:  Theranostics       Date:  2020-10-26       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.